Swiss dosimetry company ScandiDos announced today that its Delta4 Discover in-vivo dose monitoring system has received 510(k) clearance from the FDA.
The FDA clearance represents the first market availability for a device that independently verifies patient radiation doses simultaneously during treatment, according to a company press release.
“Until now, the concept of measuring the daily dose of radiation in real time, to ensure it accurately matches the patient treatment plan, did not exist. Delta4 Discover will provide this critical step in the radiation process, enhancing patient safety,” said ScandiDos CEO Görgen Nilsson.
The company, which specializes in advanced dosimetry technology and radiation quality assurance, says the new in-vivo dosimetry system will greatly increase the quality and overall safety of radiation treatment methods for cancer patients.